Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$1.40 USD
-0.07 (-4.76%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGTX 1.40 -0.07(-4.76%)
Will CGTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGTX
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGTX
50 Day Moving Average Resistance appears for CGTX after 4.76% move
CGTX Fell Below 50 Day Moving Average on September 19
Is CGTX primed for upward momentum? 50 Day Moving Average Support shows up after crashing 8.7%
Non-ADX 1,2,3,4 Bullish appears for CGTX after 4.55% move
Is CGTX heading for a slide? New Downtrend shows up after plummeting 29.03%